Australia markets open in 2 hours 43 minutes

bluebird bio, Inc. (0HOH.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
3.0379-0.0901 (-2.88%)
At close: 07:03PM BST
Full screen
Previous close3.1280
Bid0.0000 x 0
Ask0.0000 x 0
Day's range3.0041 - 3.1812
52-week range2.8550 - 8.5650
Avg. volume9,123
Market cap1.687M
Beta (5Y monthly)0.93
PE ratio (TTM)N/A
EPS (TTM)-10.4290
Earnings date06 Nov 2023 - 10 Nov 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Motley Fool

    Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio

    CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE) are at the forefront of developing gene therapies, yet the shares of both companies have underperformed the market over the last 12 months. CRISPR Therapeutics doesn't have any approved treatments on the market yet, but that'll change soon enough, which is the crux of the thesis in favor of it being a great growth stock. Through its partnership with Vertex Pharmaceuticals, it's aiming to commercialize the gene therapy exa-cel, which was developed to provide a functional cure for both beta-thalassemia and sickle cell disease.

  • Motley Fool

    More Likely to 5x First: Bluebird Bio vs. CRISPR Therapeutics

    Gene editing is a relatively new technology that allows scientists to modify an organism's DNA. Two companies that are hard at work in this field are Bluebird Bio (NASDAQ: BLUE) and CRISPR Therapeutics (NASDAQ: CRSP). Bluebird Bio currently has two approved gene-editing therapies on the market.

  • Motley Fool

    2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street

    Investors looking for stocks that can put up dramatic gains in a short amount of time naturally flock to biotech stocks. Up and down Wall Street, the investment bank analysts have been telling anyone who'll listen to buy these biotech stocks before they soar. The average price target on these stocks suggests some dramatic gains could be up ahead.